Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma

Gynecologic Oncology

Volumn 127, Issue 2, 2012, Pages 412-419

  Feng, Qinghua ^a   Wei, Huafeng ^a   Morihara, Janice ^a   Stern, Joshua ^a   Yu, Mujun ^b   Kiviat, Nancy ^a   Hellstrom, Ingegerd ^a   Hellstrom, Karl Erik ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Medical Laboratory Associates   (United States)

Author keywords

Cervical cancer; HPV; Immunosuppression; Th 2 inflammation; Tumorgenesis

Indexed keywords

CD20 ANTIGEN; FC RECEPTOR IIB; INTERLEUKIN 10; SYNDECAN 1; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TH2 CELL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CERVICAL INTRAEPITHELIAL NEOPLASIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; INTERLEUKIN-10; MICE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RECEPTORS, CYTOKINE; TH2 CELLS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84867405313     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.07.098     Document Type: Article

References (64)

1. K.E. Hellstrom, and J.P. Brown Tumor antigens M. Sela, The antigens 5 1979 Academic Press N.Y. 1 82
2. T. Boon, J.C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel Tumor antigens recognized by T lymphocytes Annu Rev Immunol 12 1994 337 365
3. S.A. Rosenberg Progress in human tumour immunology and immunotherapy Nature 411 2001 380 384
4. F. Balkwill, and A. Mantovani Inflammation and cancer: back to Virchow? Lancet 357 2001 539 545
5. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation, and cancer Cell 140 2010 883 899
6. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
7. H. zur Hausen Viruses in human cancers Eur J Cancer 35 1999 1878 1885
8. L. Chen, M.T. Mizuno, M.C. Singhal, S.L. Hu, D.A. Galloway, and I. Hellstrom Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16 J Immunol 148 1992 2617 2621
9. L.P. Chen, E.K. Thomas, S.L. Hu, I. Hellstrom, and K.E. Hellstrom Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen Proc Natl Acad Sci U S A 88 1991 110 114
10. G.G. Kenter, M.J. Welters, A.R. Valentijn, M.J. Lowik, D.M. Berends-van der Meer, and A.P. Vloon Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N Engl J Med 361 2009 1838 1847
11. M. van den Hende, A. Redeker, K.M. Kwappenberg, K.L. Franken, J.W. Drijfhout, and J. Oostendorp Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-specific CD4 + memory T cell responses J Infect Dis 202 2010 1200 1211
12. H. zur Hausen Papillomaviruses in the causation of human cancers - a brief historical account Virology 384 2009 260 265
13. H.O. Sjogren Studies on specific transplantation resistance against polyoma virus-induced tumors. IV. Stability of the polyoma cell antigen J Natl Cancer Inst 32 1964 661 666
14. J. Cuzick, C.J. Meijer, and J.M. Walboomers Screening for cervical cancer Lancet 351 1998 1439 1440
15. T.V. Sedlacek Advances in the diagnosis and treatment of human papillomavirus infections Clin Obstet Gynecol 42 1999 206 220
16. M.H. Stoler, and M. Schiffman Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study JAMA 285 2001 1500 1505
17. N.B. Kiviat, L.A. Koutsky, J.A. Paavonen, D.A. Galloway, C.W. Critchlow, and A.M. Beckmann Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic J Infect Dis 159 1989 293 302
18. M.E. Sherman, M.H. Schiffman, A.T. Lorincz, M.M. Manos, D.R. Scott, and R.J. Kuman Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types Am J Clin Pathol 102 1994 182 187
19. B.C. Sheu, R.H. Lin, H.C. Lien, H.N. Ho, S.M. Hsu, and S.C. Huang Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer J Immunol 167 2001 2972 2978
20. I.T. Ovestad, E. Gudlaugsson, I. Skaland, A. Malpica, A.J. Kruse, and E.A. Janssen Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression Mod Pathol 23 2010 1231 1240
21. W. Zou Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat Rev Cancer 5 2005 263 274
22. W.L. Byrne, K. Mills, J.A. Lederer, and G.C. O'Sullivan Targeting regulatory T cells in cancer Cancer Res 71 2011 6915 6920
23. N. Bh CD20 + B cells: the other tumor-infiltrating lymphocytes J Immunol 185 2010 4977 4982
24. R.D. Sanderson, and M. Borset Syndecan-1 in B lymphoid malignancies Ann Hematol 81 2002 125 135
25. P. Selvaraj, N. Fifadara, S. Nagarajan, A. Cimino, and G. Wang Functional regulation of human neutrophil Fc gamma receptors Immunol Res 29 2004 219 230
26. J. Ravetch, and S. Bolland IgG Fc receptors Annu Rev Immunol 19 2001 275 290
27. J.C. Massacand, R.C. Stettler, R. Meier, N.E. Humphreys, R.K. Grencis, and B.J. Marsland Helminth products bypass the need for TSLP in Th2 immune responses by directly modulating dendritic cell function Proc Natl Acad Sci U S A 106 2009 13968 13973
28. S.F. Ziegler, and D. Artis Sensing the outside world: TSLP regulates barrier immunity Nat Immunol 11 2010 289 293
29. T. Ito, Y.H. Wang, O. Duramad, T. Hori, G.J. Delespesse, and N. Watanabe TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand J Exp Med 202 2005 1213 1223
30. D.H. Munn Indoleamine 2,3-dioxygenase, Tregs and cancer Curr Med Chem 18 2011 2240 2246
31. V.P. Balachandran, CM, S. Zeng, Z.M. Bamboat, L.M. Ocuin, and H. Obaid Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido Nat Med 17 2011 1094 1100
32. L. De Monte, M. Reni, E. Tassi, D. Clavenna, I. Papa, and H. Recalde Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer J Exp Med 208 2011 469 478
33. A. Pedroza-Gonzalez, K. Xu, T.C. Wu, C. Aspord, S. Tindle, and F. Marches Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation J Exp Med 208 2011 479 490
34. W. Ouyang, S. Rutz, N.K. Crellin, P.A. Valdez, and S.G. Hymowitz Regulation and functions of the IL-10 family of cytokines in inflammation and disease Annu Rev Immunol 29 2011 71 109
35. K.K. Azar, M. Tani, H. Yasuda, A. Sakai, M. Inoue, and T. Sasagawa Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions Hum Pathol 35 2004 1376 1384
36. M. Clerici, M. Merola, E. Ferrario, D. Trabattoni, M.L. Villa, and B. Stefanon Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection J Natl Cancer Inst 89 1997 245 250
37. R. Mindiola, D. Caulejas, J. Nunez-Troconis, M. Araujo, M. Delgado, and J. Mosquera Increased number of IL-2, IL-2 receptor and IL-10 positive cells in premalignant lesions of the cervix Invest Clin 49 2008 533 545
38. S. Detre, G. Saclani Jotti, and M. Dowsett A quickscore method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas J Clin Pathol 48 1995 876 878
39. M.C. Feltkamp, G.R. Vreugdenhil, M.P. Vierboom, E. Ras, S.H. van der Burg, and J. ter Schegget Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors Eur J Immunol 25 1995 2638 2642
40. M.C. Feltkamp, H.L. Smits, M.P. Vierboom, R.P. Minnaar, B.M. de Jongh, and J.W. Drijfhout Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells Eur J Immunol 23 1993 2242 2249
41. K.E. Hellstrom, and I. Hellstrom Vaccines to treat cancer - an old approach whose time has arrived J Cell Biochem 102 2007 291 300
42. A.B. Moscicki, J.H. Ellenberg, P. Crowley-Nowick, T.M. Darragh, J. Xu, and S. Fahrat Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents J Infect Dis 190 2004 1413 1421
43. Y. Liu, S. Tuve, J. Persson, I. Beyer, R. Yumul, and Z.Y. Li Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models Cancer Gene Ther 18 2011 407 418
44. S. Tuve, B.M. Chen, Y. Liu, T.L. Cheng, P. Toure, and P.S. Sow Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses Cancer Res 67 2007 5929 5939
45. A. Kobayashi, V. Weinberg, T. Darragh, and K. Smith-McCune Evolving immunosuppressive microenvironment during human cervical carcinogenesis Mucosal Immunol 1 2008 412 420
46. C. Fotopoulou, J. Sehouli, R. Pschowski, S. VONH, G. Domanska, and E.I. Braicu Systemic changes of tryptophan catabolites via the indoleamine-2,3- dioxygenase pathway in primary cervical cancer Anticancer Res 31 2011 2629 2635
47. T. Nakamura, T. Shima, A. Saeki, T. Hidaka, A. Nakashima, and O. Takikawa Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer Cancer Sci 98 2007 874 881
48. G. Moller Effect on tumor growth in syngeneic recipients of antibodies against tumor-specific antigens in methylcholanthrene-induced mouse sarcomas Nature 204 1964 846 847
49. I. Hellstrom, K.E. Hellstrom, C.A. Evans, G.H. Heppner, G.E. Pierce, and J.P. Yang Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens Proc Natl Acad Sci U S A 62 1969 362 368
50. H.O. Sjogren, I. Hellstrom, S.C. Bansal, and K.E. Hellstrom Suggestive evidence that the blocking antibodies of tumor-bearing individuals may be antigen-antibody complexes Proc Natl Acad Sci U S A 68 1971 1372 1375
51. R.W. Baldwin, M.R. Price, and R.A. Robins Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes Nature 238 1972 185 187
52. K.E. Hellstrom, and I. Hellstrom Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens Adv Immunol 18 1974 209 277
53. K.E. de Visser, L.V. Korets, and L.M. Coussens De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent Cancer Cell 7 2005 411 423
54. P. Andreu, M. Johansson, N.I. Affara, F. Pucci, T. Tan, and S. Junankar FcRgamma activation regulates inflammation-associated squamous carcinogenesis Cancer Cell 17 2010 121 134
55. K. Zumbach, F. Kisseljov, O. Sacharova, G. Shaichaev, L. Semjonova, and L. Pavlova Antibodies againsdt oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia Int J Cancer 85 2000 313 318
56. A. Ravaggi Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characterristics of cervical cancer patients Arch Virol 151 2006 1899 1916
57. M.Y. Tjiong, K. Zumbach, J.T. Ter Schegget, N. Van der Vange, T.A. Out, and M. Pawlita Antibodies against human papillomavirus type 16 and 18 E6 and E7 proteins in cervicovaginal washings and serum of patients with cervical neoplasia Viral Immunol 14 2001 415 424
58. K.M. Dhodapkar, J.L. Kaufman, M. Ehlers, D.K. Banerjee, E. Bonvini, and S. Koenig Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells Proc Natl Acad Sci U S A 102 2005 2910 2915
59. A.M. Boruchov, G. Heller, M.C. Veri, E. Bonvini, J.V. Ravetch, and J.W. Young Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions J Clin Invest 115 2005 2914 2923
60. F. Li, and J.V. Ravetch Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies Science 333 2011 1030 1034
61. A.M. Kalergis, and J.V. Ravetch Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells J Exp Med 195 2002 1653 1659
62. A. Pedroza-Gonzalez, K. Xu, T.C. Wu, C. Aspord, S. Tindle, and F. Marches Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation J Exp Med 208 2011 479 490
63. L. De Monte, M. Reni, E. Tassi, D. Clavenna, I. Papa, and H. Recalde Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer J Exp Med 208 2011 469 478
64. R.T. Prehn The immune response as a stimulator of tumor growth Science 176 1972 170 171